347 related articles for article (PubMed ID: 30753972)
1. Cross-domain correlates of cannabis use disorder severity among young adults.
Schuster RM; Hareli M; Moser AD; Lowman K; Gilman J; Ulysse C; Schoenfeld D; Evins AE
Addict Behav; 2019 Jun; 93():212-218. PubMed ID: 30753972
[TBL] [Abstract][Full Text] [Related]
2. Distress intolerance moderation of motivated attention to cannabis and negative stimuli after induced stress among cannabis users: an ERP study.
Macatee RJ; Okey SA; Albanese BJ; Schmidt NB; Cougle JR
Addict Biol; 2019 Jul; 24(4):717-729. PubMed ID: 29737034
[TBL] [Abstract][Full Text] [Related]
3. Psychosocial functioning among regular cannabis users with and without cannabis use disorder.
Foster KT; Arterberry BJ; Iacono WG; McGue M; Hicks BM
Psychol Med; 2018 Aug; 48(11):1853-1861. PubMed ID: 29173210
[TBL] [Abstract][Full Text] [Related]
4. Correlates of lifetime cannabis use and cannabis use severity in a Canadian university sample.
Mader J; Smith JM; Afzal AR; Szeto ACH; Winters KC
Addict Behav; 2019 Nov; 98():106015. PubMed ID: 31233947
[TBL] [Abstract][Full Text] [Related]
5. Association of Cannabis Use With Self-harm and Mortality Risk Among Youths With Mood Disorders.
Fontanella CA; Steelesmith DL; Brock G; Bridge JA; Campo JV; Fristad MA
JAMA Pediatr; 2021 Apr; 175(4):377-384. PubMed ID: 33464286
[TBL] [Abstract][Full Text] [Related]
6. Anxiety and cannabis-related problem severity among dually diagnosed outpatients: The impact of false safety behaviors.
Buckner JD; Zvolensky MJ; Ecker AH; Jeffries ER; Lemke AW; Dean KE; Businelle MS; Gallagher MW
Addict Behav; 2017 Jul; 70():49-53. PubMed ID: 28214433
[TBL] [Abstract][Full Text] [Related]
7. Executive attention impairment in adolescents with schizophrenia who have used cannabis.
Epstein KA; Kumra S
Schizophr Res; 2014 Aug; 157(1-3):48-54. PubMed ID: 24875171
[TBL] [Abstract][Full Text] [Related]
8. Association Between Recreational Marijuana Legalization in the United States and Changes in Marijuana Use and Cannabis Use Disorder From 2008 to 2016.
Cerdá M; Mauro C; Hamilton A; Levy NS; Santaella-Tenorio J; Hasin D; Wall MM; Keyes KM; Martins SS
JAMA Psychiatry; 2020 Feb; 77(2):165-171. PubMed ID: 31722000
[TBL] [Abstract][Full Text] [Related]
9. Examining Associations Between Cannabis Use Disorder and Measures of Weekly and Within-Day Cannabis Frequency, Quantity, and Potency in College Students.
Piercey CJ; Mataczynski M; Stallsmith VT; Emery NN; Karoly HC
Cannabis Cannabinoid Res; 2024 Jun; 9(3):e917-e923. PubMed ID: 37699241
[No Abstract] [Full Text] [Related]
10. Prevalence and correlates of treatment utilization among adults with cannabis use disorder in the United States.
Wu LT; Zhu H; Mannelli P; Swartz MS
Drug Alcohol Depend; 2017 Aug; 177():153-162. PubMed ID: 28599214
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and effects of galantamine on cognition in humans with cannabis use disorder.
Sugarman DE; De Aquino JP; Poling J; Sofuoglu M
Pharmacol Biochem Behav; 2019 Jun; 181():86-92. PubMed ID: 31082417
[TBL] [Abstract][Full Text] [Related]
12. Probability and correlates of transition from cannabis use to DSM-5 cannabis use disorder: Results from a large-scale nationally representative study.
Feingold D; Livne O; Rehm J; Lev-Ran S
Drug Alcohol Rev; 2020 Feb; 39(2):142-151. PubMed ID: 31916333
[TBL] [Abstract][Full Text] [Related]
13. Cannabis use, cannabis use disorder and mental health disorders among pregnant and postpartum women in the US: A nationally representative study.
Brown QL; Shmulewitz D; Sarvet AL; Young-Wolff KC; Howard T; Hasin DS
Drug Alcohol Depend; 2023 Jul; 248():109940. PubMed ID: 37267745
[TBL] [Abstract][Full Text] [Related]
14. Who responds best to text-delivered cannabis use disorder treatment? A randomized clinical trial with young adults.
Mason MJ; Zaharakis NM; Moore M; Brown A; Garcia C; Seibers A; Stephens C
Psychol Addict Behav; 2018 Nov; 32(7):699-709. PubMed ID: 30265057
[TBL] [Abstract][Full Text] [Related]
15. Gender differences in health-related quality of life among cannabis users: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
Lev-Ran S; Imtiaz S; Taylor BJ; Shield KD; Rehm J; Le Foll B
Drug Alcohol Depend; 2012 Jun; 123(1-3):190-200. PubMed ID: 22143039
[TBL] [Abstract][Full Text] [Related]
16. Integrated cognitive behavioral therapy for comorbid cannabis use and anxiety disorders: A pilot randomized controlled trial.
Buckner JD; Zvolensky MJ; Ecker AH; Schmidt NB; Lewis EM; Paulus DJ; Lopez-Gamundi P; Crapanzano KA; Bakhshaie J
Behav Res Ther; 2019 Apr; 115():38-45. PubMed ID: 30442329
[TBL] [Abstract][Full Text] [Related]
17. Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder.
Tomko RL; Baker NL; Hood CO; Gilmore AK; McClure EA; Squeglia LM; McRae-Clark AL; Sonne SC; Gray KM
Psychopharmacology (Berl); 2020 Feb; 237(2):479-490. PubMed ID: 31712969
[TBL] [Abstract][Full Text] [Related]
18. Integrated cognitive-behavioral therapy for comorbid cannabis use and anxiety disorders: The impact of severity of cannabis use.
Buckner JD; Morris PE; Zvolensky MJ
Exp Clin Psychopharmacol; 2021 Jun; 29(3):272-278. PubMed ID: 34264732
[TBL] [Abstract][Full Text] [Related]
19. Executive functions and behavioral economic demand for cannabis among young adults: Indirect associations with cannabis consumption and cannabis use disorder.
Coelho SG; Hendershot CS; Aston ER; Ruocco AC; Quilty LC; Tyndale RF; Wardell JD
Exp Clin Psychopharmacol; 2024 Jun; 32(3):305-315. PubMed ID: 37732960
[TBL] [Abstract][Full Text] [Related]
20. Construct validity of DSM-5 cannabis use disorder diagnosis and severity levels in adults with problematic substance use.
Fink DS; Shmulewitz D; Mannes ZL; Stohl M; Livne O; Wall M; Hasin DS
J Psychiatr Res; 2022 Nov; 155():387-394. PubMed ID: 36182768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
